S&P 500   3,848.98 (-0.11%)
DOW   31,096.87 (-0.25%)
QQQ   325.58 (-0.24%)
AAPL   138.10 (+0.90%)
MSFT   227.49 (+1.12%)
FB   275.76 (+1.06%)
GOOGL   1,898.02 (+0.74%)
AMZN   3,294.39 (-0.38%)
TSLA   837.66 (-0.87%)
NVDA   552.41 (-0.41%)
BABA   258.95 (-0.40%)
CGC   33.31 (-0.74%)
GE   11.09 (+0.18%)
MU   82.79 (-2.61%)
AMD   93.32 (+1.96%)
NIO   61.22 (+4.94%)
T   28.92 (+0.31%)
F   11.40 (-1.13%)
ACB   10.43 (-6.62%)
BA   205.09 (-1.12%)
DIS   173.00 (+1.00%)
NFLX   571.48 (-1.44%)
GILD   67.29 (+0.46%)
S&P 500   3,848.98 (-0.11%)
DOW   31,096.87 (-0.25%)
QQQ   325.58 (-0.24%)
AAPL   138.10 (+0.90%)
MSFT   227.49 (+1.12%)
FB   275.76 (+1.06%)
GOOGL   1,898.02 (+0.74%)
AMZN   3,294.39 (-0.38%)
TSLA   837.66 (-0.87%)
NVDA   552.41 (-0.41%)
BABA   258.95 (-0.40%)
CGC   33.31 (-0.74%)
GE   11.09 (+0.18%)
MU   82.79 (-2.61%)
AMD   93.32 (+1.96%)
NIO   61.22 (+4.94%)
T   28.92 (+0.31%)
F   11.40 (-1.13%)
ACB   10.43 (-6.62%)
BA   205.09 (-1.12%)
DIS   173.00 (+1.00%)
NFLX   571.48 (-1.44%)
GILD   67.29 (+0.46%)
S&P 500   3,848.98 (-0.11%)
DOW   31,096.87 (-0.25%)
QQQ   325.58 (-0.24%)
AAPL   138.10 (+0.90%)
MSFT   227.49 (+1.12%)
FB   275.76 (+1.06%)
GOOGL   1,898.02 (+0.74%)
AMZN   3,294.39 (-0.38%)
TSLA   837.66 (-0.87%)
NVDA   552.41 (-0.41%)
BABA   258.95 (-0.40%)
CGC   33.31 (-0.74%)
GE   11.09 (+0.18%)
MU   82.79 (-2.61%)
AMD   93.32 (+1.96%)
NIO   61.22 (+4.94%)
T   28.92 (+0.31%)
F   11.40 (-1.13%)
ACB   10.43 (-6.62%)
BA   205.09 (-1.12%)
DIS   173.00 (+1.00%)
NFLX   571.48 (-1.44%)
GILD   67.29 (+0.46%)
S&P 500   3,848.98 (-0.11%)
DOW   31,096.87 (-0.25%)
QQQ   325.58 (-0.24%)
AAPL   138.10 (+0.90%)
MSFT   227.49 (+1.12%)
FB   275.76 (+1.06%)
GOOGL   1,898.02 (+0.74%)
AMZN   3,294.39 (-0.38%)
TSLA   837.66 (-0.87%)
NVDA   552.41 (-0.41%)
BABA   258.95 (-0.40%)
CGC   33.31 (-0.74%)
GE   11.09 (+0.18%)
MU   82.79 (-2.61%)
AMD   93.32 (+1.96%)
NIO   61.22 (+4.94%)
T   28.92 (+0.31%)
F   11.40 (-1.13%)
ACB   10.43 (-6.62%)
BA   205.09 (-1.12%)
DIS   173.00 (+1.00%)
NFLX   571.48 (-1.44%)
GILD   67.29 (+0.46%)
Log in
NASDAQ:RLMD

Relmada Therapeutics News Headlines

$36.04
+0.55 (+1.55 %)
(As of 01/22/2021 01:23 PM ET)
Add
Compare
Today's Range
$34.94
Now: $36.04
$36.58
50-Day Range
$31.38
MA: $33.40
$39.28
52-Week Range
$23.25
Now: $36.04
$54.00
Volume2,580 shs
Average Volume74,874 shs
Market Capitalization$585.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53

Headlines

Relmada Therapeutics (NASDAQ RLMD) News Headlines Today

Source:
SourceHeadline
 Brokerages Anticipate Relmada Therapeutics, Inc. (NASDAQ:RLMD) Will Post Earnings of -$1.11 Per Share Brokerages Anticipate Relmada Therapeutics, Inc. (NASDAQ:RLMD) Will Post Earnings of -$1.11 Per Share
americanbankingnews.com - January 22 at 12:22 PM
Will 2021 Continue To Be An Exciting Year For Relmada Therapeutics?Will 2021 Continue To Be An Exciting Year For Relmada Therapeutics?
nasdaq.com - January 13 at 8:21 AM
Relmada Therapeutics (NASDAQ:RLMD) Shares Up 12%Relmada Therapeutics (NASDAQ:RLMD) Shares Up 12%
americanbankingnews.com - January 12 at 7:14 PM
Relmada Therapeutics, Inc. (OTCMKTS:RLMD) Receives Consensus Recommendation of "Hold" from AnalystsRelmada Therapeutics, Inc. (OTCMKTS:RLMD) Receives Consensus Recommendation of "Hold" from Analysts
americanbankingnews.com - January 4 at 4:24 AM
Zacks: Brokerages Anticipate Relmada Therapeutics, Inc. (NASDAQ:RLMD) to Announce -$0.86 EPSZacks: Brokerages Anticipate Relmada Therapeutics, Inc. (NASDAQ:RLMD) to Announce -$0.86 EPS
americanbankingnews.com - December 30 at 3:14 PM
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 1.3%Relmada Therapeutics (NASDAQ:RLMD) Trading Down 1.3%
americanbankingnews.com - December 29 at 3:16 AM
Is RLMD A Good Stock To Buy Now?Is RLMD A Good Stock To Buy Now?
finance.yahoo.com - December 9 at 4:19 PM
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive DisorderRelmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
finance.yahoo.com - December 7 at 9:12 AM
We Think Relmada Therapeutics (NASDAQ:RLMD) Can Afford To Drive Business GrowthWe Think Relmada Therapeutics (NASDAQ:RLMD) Can Afford To Drive Business Growth
finance.yahoo.com - December 3 at 8:42 AM
Relmada Therapeutics to Participate in Upcoming Investor ConferencesRelmada Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 17 at 9:27 AM
Relmada Therapeutics, Inc. Common Stock (RLMD)Relmada Therapeutics, Inc. Common Stock (RLMD)
nasdaq.com - October 23 at 12:02 AM
Oppenheimer: These 2 “Strong Buy” Stocks Are Poised to Surge by Over 80%Oppenheimer: These 2 “Strong Buy” Stocks Are Poised to Surge by Over 80%
finance.yahoo.com - July 17 at 10:41 AM
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
finance.yahoo.com - July 13 at 1:05 PM
Relmada Therapeutics Inc.Relmada Therapeutics Inc.
www.marketwatch.com - July 9 at 7:25 PM
We're Not Worried About Relmada Therapeutics's (NASDAQ:RLMD) Cash BurnWe're Not Worried About Relmada Therapeutics's (NASDAQ:RLMD) Cash Burn
finance.yahoo.com - June 26 at 8:11 AM
Hedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)Hedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)
finance.yahoo.com - June 24 at 5:57 PM
BRIEF-Relmada Therapeutics Announces Notice Of Allowance For Patent In CanadaBRIEF-Relmada Therapeutics Announces Notice Of Allowance For Patent In Canada
www.reuters.com - June 23 at 10:24 AM
Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceRelmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
finance.yahoo.com - June 9 at 9:21 AM
Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare ConferenceRelmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
finance.yahoo.com - May 29 at 9:47 AM
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive DisorderRelmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
finance.yahoo.com - May 27 at 8:08 AM
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of OperationsRelmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
finance.yahoo.com - May 26 at 8:41 AM
SunTrust sees 90% upside in Relmada Therapeutics in premarket analyst actionSunTrust sees 90% upside in Relmada Therapeutics in premarket analyst action
seekingalpha.com - May 4 at 9:25 AM
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory AffairsRelmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
finance.yahoo.com - April 28 at 11:21 AM
Goldman Sachs: 2 Stocks That Could Climb Over 60%Goldman Sachs: 2 Stocks That Could Climb Over 60%
finance.yahoo.com - April 27 at 9:48 AM
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and SafetyRelmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
finance.yahoo.com - March 31 at 11:18 AM
Should You Take Comfort From Insider Transactions At Relmada Therapeutics, Inc. (NASDAQ:RLMD)?Should You Take Comfort From Insider Transactions At Relmada Therapeutics, Inc. (NASDAQ:RLMD)?
finance.yahoo.com - March 28 at 12:03 PM
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug DevelopmentRelmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
finance.yahoo.com - March 24 at 9:11 AM
Relmada Therapeutics: A Promising Depression Focused Player For 2020Relmada Therapeutics: A Promising Depression Focused Player For 2020
seekingalpha.com - February 17 at 12:37 PM
Relmada Therapeutics Announces $6.9 Million Private PlacementRelmada Therapeutics Announces $6.9 Million Private Placement
www.bloomberg.com - February 14 at 10:58 PM
70 Biggest Movers From Yesterday70 Biggest Movers From Yesterday
www.msn.com - December 12 at 11:08 PM
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common StockSichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
finance.yahoo.com - December 10 at 8:40 AM
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesRelmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 9 at 6:14 PM
AUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims WorkforceAUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims Workforce
www.nasdaq.com - December 5 at 12:03 AM
Alexander Capital, L.P. Congratulates Relmada Therapeutics, Inc. on Its $100 Million FinancingAlexander Capital, L.P. Congratulates Relmada Therapeutics, Inc. on Its $100 Million Financing
www.baystreet.ca - December 4 at 7:03 PM
Relmada Therapeutics Announces Pricing of Public Offering of Common StockRelmada Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 3 at 11:32 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - November 19 at 5:09 PM
Relmada Therapeutics, Inc. Rings the Opening BellRelmada Therapeutics, Inc. Rings the Opening Bell
www.nasdaq.com - October 28 at 5:47 PM
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
finance.yahoo.com - October 17 at 1:30 PM
BRIEF-Relmada Therapeutics Inc Announces Top-Line Results From REL-1017 Phase 2 Study In Individuals With Treatment Resistant DepressionBRIEF-Relmada Therapeutics Inc Announces Top-Line Results From REL-1017 Phase 2 Study In Individuals With Treatment Resistant Depression
www.msn.com - October 15 at 10:30 PM
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant DepressionRelmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
finance.yahoo.com - October 15 at 12:29 PM
Relmada Therapeutics stock rockets 137% on positive trial of depression treatmentRelmada Therapeutics stock rockets 137% on positive trial of depression treatment
finance.yahoo.com - October 15 at 12:29 PM
Relmada Therapeutics to Announce Results of Phase...Relmada Therapeutics to Announce Results of Phase...
www.benzinga.com - October 14 at 6:44 PM
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital MarketRelmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
finance.yahoo.com - October 10 at 8:55 AM
Relmada Therapeutics announces 1-for-4 reverse stock split for proposed uplisting to NASDAQRelmada Therapeutics announces 1-for-4 reverse stock split for proposed uplisting to NASDAQ
seekingalpha.com - September 27 at 4:40 PM
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital MarketRelmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
finance.yahoo.com - September 27 at 4:40 PM
Collision With Reality Sends Abeona Stock Spiraling LowerCollision With Reality Sends Abeona Stock Spiraling Lower
seekingalpha.com - July 31 at 10:11 AM
Relmada advancing depression candidate REL-1017, mid-stage data readout this quarterRelmada advancing depression candidate REL-1017, mid-stage data readout this quarter
seekingalpha.com - July 29 at 6:44 PM
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant DepressionRelmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
finance.yahoo.com - July 29 at 8:27 AM
Relmada Therapeutics to Present at LD Micro Invitational Conference in Los AngelesRelmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
finance.yahoo.com - June 3 at 9:41 AM
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology MeetingRelmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
finance.yahoo.com - May 31 at 9:50 AM
This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.